Endothelial Cell-Based Gene Therapy of Breast Cancer
Abstract
In our previously report, we demonstrated that the systemic administration of murine endothelial cells expressing human interleukin (IL)-2 gene (hIL-2-GMEC) mediated significant reductions of established pulmonary macrometastases from breast cancer. In the present study, we analyzed IL-2-GMEC-targeted and IL-2-GMEC-negative breast tumor metastases to determine the immune effector cells that may be involved in IL-2-GMEC-mediated regression of breast cancer metastases. IL-2-GMEC-negative metastases were infiltrated by granulocytes and macrophages. These cells were confined to the edges of the tumors. In contrast, rhIL-2-positive tumors had an extensive cellular infiltrate made up of granulocytes (mainly neutrophils), macrophages, CD4+ and CD8+ lymphocytes. More importantly, these cells were present around and within individual metastasis. These results suggest that both non-specific and specific immune effector cells may be involved in IL-2-GMEC-mediated regression of breast cancer metastasis.
Document Details
- Document Type
- Technical Report
- Publication Date
- Aug 01, 2001
- Accession Number
- ADA398178
Entities
People
- John O. Ojeifo
Organizations
- Georgetown University